Understanding which gene mutations occur in your patient’s tumor and how they affect cancer-related cell signaling pathways to drive tumor growth provides the key to finding a suitable personalized therapy. More and more studies highlight the strong association between the genetic alterations of a patient’s tumor and the success of using tailored targeted therapies. These targeted therapies are already commonly used for some cancer types, such as for lung cancer, but are effective in a wide variety of cancer types.
ACT Genomics performs comprehensive genetic testing for your patient’s cancer. We analyze samples by next-generation sequencing with subsequent bioinformatics data processing and then utilize clinical databases to identify most promising matching tailored treatment options for your patients!
ACT Genomics provides pan-cancer panels and cancer-specific panels to serve patients with solid tumors. The panels designed for the analysis of important genes associated with targeted therapies are ACTDrug®+ and ACTOnco®+. We offer ACTMonitor™ and ACTBRCA™ to provide further information for treatment and cancer monitoring; the panel ACTRisk™ can identify individuals with an enhanced cancer risk and enable preventive actions.
With years of experience in Next Generation Sequencing (NGS) and clinical settings, we are capable of handling various specimens, including FFPE, frozen tissue, core needle biopsy, pleural effusion and ascites samples. With just a fraction of precious specimens, we can achieve an average sequencing depth of 1,000X to detect genetic alterations with high sensitivity. We are dedicated to deliver highly accurate results that cover all aspects of cancer, from diagnosis and treatment selection to disease monitoring. Our comprehensive report, including genomic alteration status, the biological function of mutated genes, our in-house curated cancer signaling pathways and therapeutic implications, covers the most relevant clinical evidence. It supports physicians to translate genomic information into a tailored treatment and to make the best therapeutic decision for their patients.
Identify more evidence-based treatment options
We have different genomic profiling services which can satisfy individual patients’ needs. Using genetic testing before cancer treatment can help you to develop a better treatment strategies for your patients. To understand which therapy bests suits your patient, it is important to understand the mechanism driving the growth of your patient’s tumor. Since 300 to 400 genes in different cancer signaling pathways may be involved in this process, comprehensive genomic profiling services are required for thorough analysis. ACTOnco®+ is a comprehensive tumor genomic profiling service that covers more than 400 cancer-related genes to uncover the cancer mechanism of your patient and find the most appropriate matching targeted therapy based on a whole pathway analysis.
ACTDrug®+ is a tumor genetic test that precisely analyses carefully selected cancer-related genes with well-defined therapeutic implications, especially for patients with breast, lung and colorectal cancer.
ACTBRCA ™ detects germline and somatic mutations in the BRCA1/2 genes. The test is therefore capable to identify patients with breast, ovarian, prostate and pancreatic cancer that may benefit from targeted therapy by PARP inhibitors and informs about an inherited risk for developing those specific cancers.
If you would like to have a comprehensive evaluation of chemotherapy and targeted therapy choices for your patient, you may consider using our comprehensive genomic profiling service: ACTOnco®+.
If you would like to have an evaluation of targeted therapy choices for your patient, you may consider using our targeted genomic profiling service: ACTDrug ®+
If you would like to have an evaluation for specific drug choices for your patient, you may consider using our BRCA1/2 analyzing panel, ACTBRCA™
Monitor treatment efficiency using liquid biopsy
Monitoring tumor relapse and therapy success by imaging methods or traditional cancer biomarkers such as CEA only allow a delayed assessment of tumor development. These tests are less accurate than liquid biopsy tests that detect circulating tumor DNA (ctDNA) in the blood. ACTMonitor™ detects changes in the levels of ctDNA fast and accurately and therefore allows a real-time monitoring of changes in tumor burden. The test informs you about therapy success, resistance and tumor relapse very early and enables you to make faster adaptions of your patient’s treatment. If you would like to monitor treatment more effectively for your patient, you may consider using our ctDNA detection service, ACTMonitor ™
Predict Immunotherapy Response
Cancer immunotherapy can have impressive long-lasting effects, but not all patients are likely to benefit from this costly treatment. Patients treated with checkpoint inhibitors respond better to immunotherapy if their tumors harbor high mutation burden.
ACTOnco™ helps you to evaluate the patient- specific tumor mutation burden and to predict if your patient is likely to benefit from using immunotherapy with checkpoint inhibitors.
If you would like to predict if you are suitable for immunotherapy, you may consider using our immunotherapy response prediction service, ACTOnco ™
Identify hereditary cancer related genetic alterations
Approximately 5-10% of cancers are caused by inherited genetic variants (germline mutations). In addition to the well-characterized BRCA1/2, mutations in many other genes also cause a higher lifetime risk of cancer, up to 10-90 times higher than for someone without a mutation. Therefore, understanding the hereditary cancer risk can assist a medical professional to better diagnose and manage the disease.
ACTRisk™ is a fast and accurate genetic test analyzing 32 genes strongly associated with common hereditary cancers. It provides important genetic information that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with clients.
Olaparib significantly improves PFS in BRCA-mutated ovarian cancer as frontline maintenance therapy 2018-12-04
In the phase 3 SOLO-1 study, olaparib as frontline maintenance therapy showed significant PFS improvement in ovarian cancer patients carrying BRCA mutation
Rucaparib shows encouraging anti-tumor activity in metastatic castration-resistant prostate cancer with a deleterious BRCA alteration 2018-12-04
According to the preliminary data of TRITON2 study, rucaparib showed anti-tumor activity in metastatic castration-resistant prostate cancer patients carrying BRCA mutation.
FDA granted accelerated approval of lorlatinib in ALK+ NSCLC 2018-12-04
Based on data from a phase II study (B7461001), the FDA approved lorlatinib for the treatment of patients with ALK positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors (TKIs)
Infigratinib shows meaningful clinical activity in patients with intrahepatic cholangiocarcinoma (IHC) containing FGFR2 fusions 2018-12-04
According to updated phase II findings presented at the 2018 ESMO Congress, infigratinib, a selective pan-FGFR kinase inhibitor, demonstrated a clinical meaningful activity in patients with IHC.
A combination therapy can be used to control the disease of osimertinib-resistant lung cancer patients with RET gene fusion 2018-12-04
This study indicated that RET fusion mutation is one of the mechanisms of drug resistance in EGFR-mutant lung cancer patients after osimertinib treatment. A combination therapy provides a new strategy to overcome the drug resistance
FDA Approves Anti-PD-1 Antibody Cemiplimab for CSCC 2018-11-01
The U.S. FDA approves PD-1 inhibitor cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC).
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
